Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease

Expert Opinion on Drug Delivery

Volumn 5, Issue 12, 2008, Pages 1377-1386

  Winblad, Bengt ^a   Machado, João Carlos ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Hospital Mater Dei   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID COPOLYMER; ALPHA TOCOPHEROL; CARBIDOPA; CHOLINESTERASE INHIBITOR; DONEPEZIL; ENTACAPONE; GALANTAMINE; LEVODOPA; METHACRYLIC ACID METHYL ESTER; PLACEBO; RIVASTIGMINE; SILICONE; SILICONE OIL;

ALZHEIMER DISEASE; APPETITE DISORDER; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; LEG CRAMP; LOADING DRUG DOSE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NAUSEA AND VOMITING; OPTIMAL DRUG DOSE; PARKINSON DISEASE; PATIENT COMPLIANCE; SKIN PENETRATION; SKIN REDNESS; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; VERTIGO;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; PHENYLCARBAMATES; SKIN ABSORPTION;

EID: 58149203447     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240802542690     Document Type: Article

References (34)

1. Wimo A, Winblad B, Aguero-Torres H, Von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003;17(2):63-7
2. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S10-5
3. Nitrini R, Caramelli P, Herrera E Jr. et al. Incidence of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord 2004;18(4):241-6
4. Wimo A, Winblad B, Jonsson L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement 2007;3:81-91
5. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1(Suppl 1):S26-34
6. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50(1):136-45
7. Machado JC, Caramelli P. Treatment of dementia: anything new? Curr Opin Psychiatry 2006;19(6):575-80
8. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001;15(5):375-90
9. Winblad B, Jelic V. Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord 2004;18(Suppl 1):S2-8
10. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007;23(11):2705-13
11. Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother 2007;711;1457-63
12. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22(5):456-67
13. Goldsmith L. Physiology, Biochemistry; and Molecular Biology of the Skin. 2nd, edition, New York: Oxford University Press; 1991
14. Nitti VW, Sanders S, Staskin DR, et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology 2006;67(4):657-64
15. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000;9(3):165-9
16. Murphy M, Carmichael AJ. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol 2000;1(6):361-8
17. Henzl MR, Loomba PK. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. J Reprod Med 2003;48(7):525-40
18. Petersen TA. Transdermal drug formulations and process development. Pharm Technol 2003;(Suppl):18-21
19. Lefevre G, Sedek G, Jhee S, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharm Ther 2008;83(1):106-14
20. Mercier F, Lefèvre G, Huang HL, et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007;23:3199-204
21. Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69(4 Suppl 1):S10-3
22. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 1998;13(5):391-411
23. Lefèvre G, Sedek G, Huang HL, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007;47(4):471-8
24. Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006;23(5):357-75
25. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002;127:45-63
26. Jhee SS, Shiovitz T, Hartman RD, et al. Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine. Clin Neuropharmacol 2002;25(2):122-3
27. Darvesh S, Walsh R, Kumar R, et al. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17(2):117-26
28. Grossberg G. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Curr Ther Res 2003;64(4):216-35
29. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41(10):719-39
30. Winblad B, Kawata AK, Bensterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007;22(5):485-91
31. Singh G, Thomas SK, Arcona S, et al. Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J Am Geriatr Soc 2005;53(7):1269-70
32. Travis SS, Bethea LS, Winn P. Medication administration hassles reported by family caregivers of dependent elderly persons. J Gerontol A Biol Sci Med Sci 2000;55(7):M412-7
33. Blesa R, Ballard C, Orgogozo JM, et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007;69(Suppl 1):S23-8
34. WIPO. (WO/2008/021113) Transdermal methods and systems for treating Alzheimer's disease. Available from: http://wwwwipoint/pctdb/en/ wojsp?WO=2008021113&IA=WO2008021113&DISPLAY=DESC; [Last accessed 2 July 2008]